SCHEMBL1339415

SCHEMBL1339415

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(CCl)ccc3n(C)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 5/20 0.41
▸ GABRG2 P18507 5/20 0.41
▸ GABRB3 P28472 5/20 0.41
▸ GABRA5 P31644 5/20 0.41
▸ KDM4E B2RXH2 4/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ F2RL3 Q96RI0 1/20 0.37
▸ HSD11B1 P28845 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ TTR P02766 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ GSK3A P49840 2/20 0.34
▸ GSK3B P49841 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ RGS12 O14924 1/20 0.34
▸ GMNN O75496 1/20 0.34
▸ USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338690 0.90 PGR (0.39) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1340407 0.87 KDM4E (0.36) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL2382190 0.84 F2RL3 (0.46) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1339317 0.83 KDM4E (0.42) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1339369 0.83 KDM4E (0.39) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1338314 0.82 GSK3B (0.37) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1338090 0.82 KDM4E (0.52) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL2385324 0.81 ALDH1A1 (0.47) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL1339426 0.81 PTGER4 (0.47) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1338257 0.81 KDM4E (0.38) GABRA1GABRG2GABRB3GABRA5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 GABRA1 1457/4885GABRG2 1617/4885GABRB3 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback